Banner background image Banner background image

EXPLORE EXPERT PERSPECTIVES
ON LEQVIO®

Navigate through the real-world experiences and uncover invaluable insights and answers to crucial
questions specifically curated for you to gain a deeper understanding of what truly matters most.

For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy

EXPANDED INDICATION ENABLES BROADER USE OF LEQVIO

The FDA has approved the revised indication for use in patients with primary hyperlipidemia
in addition to ESTABLISHED ASCVD and HeFH

Body background image

Explore the MOA

View to learn more about how LEQVIO works differently than other LDL-C—lowering treatments as a complement to statins.

/assets/pdf/297062-LEQ-UPDATED-RNAi-Infographic-8.23-v2.pdf
Body background image

LEQVIO: From Discovery to Development

View to learn more about how LEQVIO was developed, and its unique features.

/assets/pdf/297054-LEQ-UPDATED-Discovery-to-Development-Infographic-8.23-v2.pdf
Body background image

Dive Into siRNA Technology

View to learn more about how LEQVIO—a small interfering RNA therapy that selectively targets the liver to regulate LDL-C levels.

/assets/pdf/297047-LEQ-Updated-RNA-Therapy-Infographic-8.23_FINAL.pdf
Body background image

How Is LEQVIO Dosing Different From PCSK9 mAbs?

Watch Dr Stephanie J. Saucier, Dr Richard Wright, and Matthew J. Budoff discuss the dosing regimen of LEQVIO and how it may integrate seamlessly into clinical practice.

201052 1_fxjss2g7
Body background image

How Do You Get Your Patients Started on LEQVIO?

Watch Dr Suzanne Shugg, Dr Rajkumar Sugumaran, and  Dr Prediman K. Shah discuss the flexible pathways available for acquisition and administration of patients.

222034 1_crd63beu
Body background image

LEQVIO via Buy-and-Bill With In-Office Administration

Find out more about acquiring HCP-administered products like LEQVIO through buy-and-bill, the primary method for...

241848 1_jkzyoboy
Body background image

LEQVIO via Referral to an Alternate Injection Center (AIC)

If buy-and-bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC to handle...

241849 1_0y2f5bpm

What Makes LEQVIO Different

Explore the resources below to dive even further into specific parts of the
LEQVIO story and to see what makes LEQVIO different

Body background image

LEQVIO: A Bold Way Forward

In this overview presentation, learn about what makes the LEQVIO clinical profile and dosing different

1648101222 1_bfwncktg
Body background image

Unmet Need in Patients With ASCVD

Dr Pam Taub and Dr Alan S. Brown provide insights on the state of cardiovascular disease and what makes LEQVIO such a...

1648020944 1_tgdxoad1
Body background image

Dosing and Administration: How to Give LEQVIO to Your Patients

Dr Alan S. Brown shares details on the LEQVIO dosing regimen—two doses a year after the first year—while highlighting...

1648020356 1_chjn6u8e
Body background image

LEQVIO: From Discovery to Development

LEQVIO is a small interfering RNA (siRNA) therapy that was studied in clinical trials to assess its efficacy and safety as a...

https://novartispharma.widen.net/s/rzvj2qdc2z/164659-leq-from-discovery-to-development-infographic-12.21
Body background image

How Is LEQVIO Dosing Different From PCSK9 mAbs?

Gain valuable insight from experts as they discuss how LEQVIO dosing differs from PCSK9 mAbs.

1663769565 1_fxjss2g7
Body background image

How Do You Explain the Value of LEQVIO to Your Patients?

Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.

1663777654 1_3agyet72

Mechanism of Action

Take a look and become familiar with the LEQVIO mechanism of action

Body background image

Explore the MOA

LEQVIO—harnessing the natural process of RNAi to lower LDL-C in certain patients with ASCVD on a maximally tolerated statin1

https://novartispharma.widen.net/s/tqtgjrgnkj/explore-the-moa-164678
Body background image

Dive Into siRNA Technology

LEQVIO—a asfsadfasdfsmall interfering RNA therapy that selectively targets the liver to regulate LDL-C levels1

https://novartispharma.widen.net/s/vjmwgb5xjd/dive-into-sirna-technology-164671
Body background image

Illustrated MOA

Watch the LEQVIO MOA come to life in this animated video

1663777747 1_rztg4y49
Body background image

What's Different About the Way LEQVIO Lowers LDL Cholesterol Compared to PCSK9 mAbs?

LEQVIO is not another PCSK9 monoclonal antibody. It's something else...

1663777838 1_1yvyl6dt

Clinical Trial Data: Efficacy & Safety

See what LEQVIO can do for patients like yours

Body background image

LEQVIO: A Bold Way Forward

In this overview presentation, learn about what makes the LEQVIO clinical profile and dosing different

1648101222 1_bfwncktg
Body background image

Lowering LDL-C With LEQVIO: Clinical Trial Data Overview

Dr Alan S. Brown dives deeper into pivotal phase III clinical trial data for LEQVIO for patients with ASCVD, with a focus on...

1648020553 1_xdv2fzbe
Body background image

Recap the LEQVIO Clinical Story On-the-Go

Take a moment for a refresh of the entire LEQVIO clinical story with insights into efficacy, dosing, safety, and more!

1648100806 1_lxunae4a
Body background image

ORION-10 Clinical Trial Design

ORION-10 evaluated LDL-C reduction in certain patients with ASCVD1

https://novartispharma.widen.net/s/69zc82k8fj/orion-10-clinical-trial-design-158721
Body background image

Discover Clinical Efficacy & Safety

Take a deeper look at data supporting the efficacy and safety of LEQVIO.

https://novartispharma.widen.net/s/blcvkhrlp8/discover-clinical-efficacy--safety-159040
Body background image

How Do You Explain the Value of LEQVIO to Your Patients?

Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.

1663777654 1_3agyet72

Access & Acquisition

Gain valuable access and acquisition insight by exploring the videos below

Body background image

LEQVIO via Specialty Pharmacy

Gain insights into a third acquisition option for patients to acquire LEQVIO: a specialty pharmacy for in-office administration

1648018871 1_lngn2u2g
Body background image

LEQVIO via Buy-and-Bill With In-Office Administration

Find out more about acquiring HCP-administered products like LEQVIO through buy-and-bill, the primary method for...

1648019958 1_jkzyoboy
Body background image

LEQVIO via Referral to an Alternate Injection Center (AIC)

If buy-and-bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC to handle...

1648019710 1_0y2f5bpm
Body background image

How Do You Get Your Patients Started on LEQVIO?

Watch our experts discuss the benefits of the 3 ways to acquire LEQVIO for patients.

1663778031 1_crd63beu

Expert Voices

Watch and learn what the experts have to say about LEQVIO

Body background image

Patients Who Could Benefit From LEQVIO

Dr Pam Taub and Dr Alan S. Brown describe a few types of patients from their clinics who are struggling to achieve the recommended...

1648020145 1_ze2rk93k
Body background image

How is LEQVIO Dosing Different From PCSK9 mAbs?

Gain valuable insight from experts as they discuss how LEQVIO dosing differs from PCSK9 mAbs.

1663769565 1_fxjss2g7
Body background image

What's Different About the Way LEQVIO Lowers LDL Cholesterol Compared to PCSK9 mAbs?

LEQVIO is not another PCSK9 monoclonal antibody. It's something else...

1663777838 1_1yvyl6dt
Body background image

How Do You Explain the Value of LEQVIO to Your Patients?

Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.

1663777654 1_3agyet72
Body background image

How Do You Identify Appropriate Patients with ASCVD for LEQVIO?

Follow along with our diverse panel of HCPs as they dive into the keys to identifying patients appropriate for LEQVIO.

1663777944 1_vkt6lth8
Body background image

How Do You Get Your Patients Started on LEQVIO?

Watch our experts discuss the benefits of the 3 ways to acquire LEQVIO for patients.

1663778031 1_crd63beu
THERE'S MORE TO KNOW ABOUT LEQVIO

See how LEQVIO is there to support you and your patients

EXPLORE SUPPORT
AND ACCESS arrow
THERE'S MORE TO KNOW ABOUT LEQVIO

See how LEQVIO is there to support you and your patients

EXPLORE SUPPORT
AND ACCESS arrow

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND IMPORTANT SAFETY
INFORMATION

COLLAPSE

EXPAND

EXPAND

COLLAPSE

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.000000000000062 4. Data on file. LEQVIO Coverage and Affordability. Novartis Pharmaceuticals Corp; 2023. 5. Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058 6. Data on file. Integrated Summary of Efficacy. Novartis Pharmaceuticals Corp. 7. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 8. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 9. Wright RS, Raal FJ, Koenig W, et al. ORION-8: an open-label extension trial of ORION-3/9/10/11 to assess long-term efficacy and safety of twice-yearly inclisiran in patients with high cardiovascular risk and elevated LDL-C. Abstract presented at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 10. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020(supplement):1-31. 11. Wright RS. A pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure from seven trials. Oral presentation at: American College of Cardiology Annual Conference; March 2023; New Orleans, LA. 12. Data on file. LEQVIO 3-Year Shelf Life. Novartis Pharmaceuticals Corp; 2022. 13. Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. 14. Repatha. Prescribing information. Amgen Inc. 15. Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEJMp1614154 16. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41-51. doi:10.1056/NEJMoa1609243 17. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 18. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-424. 19. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 20. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 21. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 22. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 24. Cannon CP, deLemos JA, Rosenson RS. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 25. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 26. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 27. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2023. 28. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 29. Data on file. Novartis Pharmaceuticals Corp; 2019. 30. Data on file. ORION-8 (CKJX839A12306B) Cumulative LEQVIO exposure. Novartis Pharmaceuticals Corp; 2023.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click here for LEQVIO full Prescribing Information.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.000000000000062 4. Data on file. LEQVIO Coverage and Affordability. Novartis Pharmaceuticals Corp; 2023. 5. Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 8. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 9. Wright RS, Raal FJ, Koenig W, et al. ORION-8: an open-label extension trial of ORION-3/9/10/11 to assess long-term efficacy and safety of twice-yearly inclisiran in patients with high cardiovascular risk and elevated LDL-C. Abstract presented at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 10. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020(supplement):1-31. 11. Wright RS. A pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure from seven trials. Oral presentation at: American College of Cardiology Annual Conference; March 2023; New Orleans, LA. 12. Data on file. LEQVIO 3-Year Shelf Life. Novartis Pharmaceuticals Corp; 2022. 13. Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. 14. Repatha. Prescribing information. Amgen Inc. 15. Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4-7. doi:10.1056/NEJMp1614154 16. Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41-51. doi:10.1056/NEJMoa1609243 17. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 18. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415-424. 19. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 20. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 21. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 22. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. 24. Cannon CP, deLemos JA, Rosenson RS. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 25. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 26. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. 27. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2023. 28. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 29. Data on file. Novartis Pharmaceuticals Corp; 2019. 30. Data on file. ORION-8 (CKJX839A12306B) Cumulative LEQVIO exposure. Novartis Pharmaceuticals Corp; 2023.